Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$6.2 million.

  • Myriad Genetics' Cash from Investing Activities fell 18266.67% to -$6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.3 million, marking a year-over-year decrease of 5166.67%. This contributed to the annual value of -$11.9 million for FY2024, which is 13730.41% down from last year.
  • Per Myriad Genetics' latest filing, its Cash from Investing Activities stood at -$6.2 million for Q3 2025, which was down 18266.67% from -$6.9 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Cash from Investing Activities high stood at $291.0 million for Q3 2021, and its period low was -$41.3 million during Q1 2022.
  • Over the past 5 years, Myriad Genetics' median Cash from Investing Activities value was -$6.2 million (recorded in 2025), while the average stood at $10.3 million.
  • As far as peak fluctuations go, Myriad Genetics' Cash from Investing Activities surged by 160175.44% in 2021, and later tumbled by 119090.91% in 2022.
  • Myriad Genetics' Cash from Investing Activities (Quarter) stood at -$25.9 million in 2021, then tumbled by 37.45% to -$35.6 million in 2022, then soared by 66.29% to -$12.0 million in 2023, then surged by 50.83% to -$5.9 million in 2024, then fell by 5.08% to -$6.2 million in 2025.
  • Its last three reported values are -$6.2 million in Q3 2025, -$6.9 million for Q2 2025, and -$8.3 million during Q1 2025.